This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
The Stevanato Group Vertiva™ on-body delivery system (OBDS) can be switched between basal and bolus injections, and is suitable for a wide range of subcutaneous therapies.
Vertiva™’s design consists of a single-use pod with a pre-filled and pre-loaded 3mL ISO cartridge, and a multi-use controller, offering potential sustainability and affordability benefits. These two parts communicate through a patented magnetically coupled drive mechanism. The device can adapt to different delivery profiles and enable the administration of small-molecule drugs and biologics. Vertiva™’s design is under development to cover a range of volumes up to 10mL, with samples expected to be available later this year.
In the Vertiva™ device, the cartridge is preloaded and sealed into the pod during factory assembly, allowing patients to benefit from simplified treatment initiation. The connectivity options of Vertiva™ are ready for digital health applications. Upon treatment, the pod and controller can be easily separated, and the controller can be reused, reducing the environmental impact of electronic components.
Totally programmable to deliver micro-precision basal doses and full-content bolus injections, Vertiva™ is suitable for a range of therapies, such as cardiovascular and metabolic disorders, oncology, immunology, and pain diseases. The Vertiva™ platform also can accommodate different customizations, including a primary packaging format for larger injection volumes, delivery duration, and user interface.
Stevanato Group will leverage the recently announced collaboration with Thermo Fisher Scientific to bring Vertiva™ to market. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill® cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services.
